| Literature DB >> 21600066 |
José-Antonio Gil-Gómez1, Roberto Lloréns, Mariano Alcañiz, Carolina Colomer.
Abstract
BACKGROUND: Acquired brain injury (ABI) is the main cause of death and disability among young adults. In most cases, survivors can experience balance instability, resulting in functional impairments that are associated with diminished health-related quality of life. Traditional rehabilitation therapy may be tedious. This can reduce motivation and adherence to the treatment and thus provide a limited benefit to patients with balance disorders. We present eBaViR (easy Balance Virtual Rehabilitation), a system based on the Nintendo® Wii Balance Board® (WBB), which has been designed by clinical therapists to improve standing balance in patients with ABI through motivational and adaptative exercises. We hypothesize that eBaViR, is feasible, safe and potentially effective in enhancing standing balance.Entities:
Mesh:
Year: 2011 PMID: 21600066 PMCID: PMC3120756 DOI: 10.1186/1743-0003-8-30
Source DB: PubMed Journal: J Neuroeng Rehabil ISSN: 1743-0003 Impact factor: 4.262
Characteristics of the participants
| Issue | Control group | Trial Group | Significance |
|---|---|---|---|
| NS (p = 0.858) | |||
| Male | 5 (29.4%) | 6(35.3%) | |
| Female | 3(17.7%) | 3(17.7%) | |
| 49.13 ± 21.18 | 45.78 ± 15.38 | NS (p = 0.704) | |
| NS (p = 0.657) | |||
| Stroke | 5 (29.4%) | 6 (35.3%) | |
| TBI | 1 (5.9%) | 2 (11.8%) | |
| BCN | 2 (11.8%) | 1 (5.9%) | |
| 675.50 ± 283.11 | 478.00 ± 324.77 | NS (p = 0.204) | |
The table shows the information of the patients. Age and time since injury are defined in terms of mean and standard deviation. Etiology is also expressed as a percentage of the total number of patients. NS: non-significant.
Figure 1Flow of the game. The flow of the game can be divided into: 1) Setup; 2) Calibration; 3) Gameplay; 4) Break; 5) Scores.
Figure 2Patients playing with the system. The eBaViR system consists of: 1) a WBB; 2) a PC; 3) Video display. The eBaViR system is suitable for different levels of impairment and allows the treatment to be carried out in a secure way.
Description of the balance scales and tests
| Measure | Description |
|---|---|
| A 14-item scale (measured from 0 to 4) designed to measure the balance of a person in a clinical setting. The scale ranges from 0 to 56. | |
| A functional balance measurement for people with a wide range of abilities; it has been specifically tested for post-stroke use in a clinical setting. The scale ranges from 0 to 14. | |
| Maximum distance that the hand can be extended forward. The patient extends one arm to an angle of 90 degrees, while standing with legs about shoulder- width apart. The test can be run in sitting (ART-sit) or standing (ART-stand) position. | |
| Time required to climb and to descend five 8 cm high steps with handrails on both sides. | |
| Times that the patient is able to place one foot onto a 7.5 cm high step and then back down to the floor within 15 seconds. The action is repeated as fast as possible during the test for the paretic and non-paretic leg. The step is placed 5 cm in front of the individual's feet. | |
| Walking distance within a minute along an 8-shaped path that is 20 m long defined on a straight and nonslip surface. | |
| Time to walk 10 m on a straight and nonslip surface. | |
| Stop-watch measurement of the time taken for a return trip to a pole placed 5 m ahead, with the subject starting from a seated position in a chair. | |
| Repetitions of rising exercise from a sitting position on a bench. |
A brief description of the scales and tests used in the study. The Berg and Brunel scales are widely used to assess the balance condition in a clinical setting. The tests are identified with the acronyms in brackets. The TST, 1MWT, 10MT, TUG, 30SST are commonly used in the literature. The ART and ST are defined above. The tests are identified with the acronyms in brackets.
Clinical data
| Significance | ||||
|---|---|---|---|---|
| Control | 45.38 ± 7.35 | 46.88 ± 6.15 | 1.50 ± 1.31 | T**(p = 0.000) |
| Trial | 41.22 ± 10.57 | 45.44 ± 8.62 | 4.22 ± 2.33 | GxT*(p = 0.011) |
| Control | 11.00 ± .1.31 | 11.13 ± 1.13 | 0.12 ± 0.35 | T*(p = 0.048) |
| Trial | 10.00 ± 2.00 | 10.33 ± 2.18 | 0.33 ± 0.50 | |
| Control | 25.44 ± 9.33 | 25.63 ± 9.74 | 0.19 ± 1.56 | T**(p = 0.005) |
| Trial | 24.13 ± 7.70 | 27.25 ± 10.38 | 3.12 ± 2.36 | GxT*(p = 0.011) |
| Control | 40.06 ± 6.87 | 40.13 ± 7.66 | 0.06 ± 6.35 | NS |
| Trial | 34.83 ± 11.92 | 37.78 ± 12.34 | 2.94 ± 4.05 | |
| Control | 6.57 ± 2.30 | 7.57 ± 2.44 | 1.00 ± 1.29 | T*(p = 0.021) |
| Trial | 6.75+3.58 | 7.63 ± 4.00 | 0.87 ± 1.46 | |
| Control | 8.17 ± 1.72 | 9.50 ± 3.39 | 1.33 ± 1.97 | T*(p = 0.046) |
| Trial | 9.33 ± 2.81 | 10.50 ± 3.02 | 1.16 ± 1.83 | |
| Control | 14.82 ± 9.42 | 12.13 ± 4.94 | -2.69 ± 6.19 | NS |
| Trial | 15.38 ± 9.69 | 13.52 ± 9.60 | -1.86 ± 4.67 | |
| Control | 31.13 ± 13.59 | 36.38 ± 15.39 | 5.25 ± 3.99 | T**(p = 0.007) |
| Trial | 31.94 ± 12.47 | 42.69 ± 20.43 | 10.75 ± 13.78 | |
| Control | 14.57 ± 10.95 | 14.07 ± 9.02 | -0.50 ± 2.16 | NS |
| Trial | 13.47 ± 8.29 | 13.47 ± 10.64 | -0.00 ± 2.60 | |
| Control | 24.00 ± 14.87 | 19.52 ± 10.91 | -4.48 ± 4.98 | T**(p = 0.004) |
| Trial | 20.99 ± 15.11 | 18.69 ± 13.43 | -2.30 ± 2.33 | |
| Control | 6.88 ± 3.52 | 8.50 ± 3.12 | 1.62 ± 1.68 | T**(p = 0.003) |
| Trial | 7.56 ± 4.19 | 9.00 ± 4.74 | 1.44 ± 1.81 |
Numerical data of the scores of scales and tests. The results are given in terms of mean () and standard deviation (σ). The subindexes 0 and 20 represent the assessments carried out before and after the treatment, respectively. G: group effect. T: time effect. GxT: group/time effect. * p < 0.05, ** p < 0.01. n represents the number of repetitions.